Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 168460 participants.

Also called NCT07485283

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 168,460 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07485283
  • EU CT 2025-524944-37-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07485283. Randomized; no masking; primary purpose prevention. Start 2026-04-28 (actual); primary completion 2029-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
Acronym
DAN-ZOSTER
Condition
Cardiovascular Disease
Condition
Dementia
Intervention (Biological)
Recombinant Herpes Zoster Vaccine (Shingrix)
Lead sponsor
Tor Biering-Sørensen (class: other)
Collaborator
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct07485283
Content hash
4ebc27494e64407ebeaa60b8fe970018383dd2ee3ed1481fe04edac178404c4f